These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8744648)

  • 1. Growth inhibition of transplantable tumors in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent.
    Pajtasz-Piasecka E; Kuśnierczyk H; Salwa J; Konarski L; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):281-92. PubMed ID: 8744648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
    Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination therapy of experimental murine hepatoma with mIL-12 gene and MHC I gene mediated by liposome].
    Wang KM; Xia AD; Chen SS
    Ai Zheng; 2002 Oct; 21(10):1041-6. PubMed ID: 12508639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy of plasmacytoma: comparison of the therapeutic efficacy of tumour cells transduced with the interleukin-2, interleukin-4, or interleukin-6 genes.
    Bubeník J; Símová J; Zeuthen J; Diamant M; Jandlová T; Bubeníková D
    Folia Biol (Praha); 1994; 40(1-2):29-36. PubMed ID: 7958062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
    Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection.
    Bulfone-Paus S; von Bernuth H; Rückert R; Wachtlin J; Ungureanu D; Notter M; Krause H; Pohl T; Paus R; Kunzendorf U
    Cancer Res; 1998 Jul; 58(13):2707-10. PubMed ID: 9661877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of biological response modifiers against transplantable mouse tumors of spontaneous origin. I. Characterization of biological properties of tumor lines and preliminary data on response to cytostatic drugs and biomodulators.
    Fiszer-Maliszewska L; Mordarski M; Madej JA
    Arch Immunol Ther Exp (Warsz); 1993; 41(1):1-9. PubMed ID: 8239902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells.
    Sobotkova E; Duskova M; Tachezy R; Petrackova M; Vonka V
    Oncol Rep; 2009 Mar; 21(3):793-9. PubMed ID: 19212641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
    Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
    J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma.
    Kimura Y; Mizuno H; Satake K; Tahara H; Tsukuda M
    Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1181-5. PubMed ID: 14623747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
    Moriguchi Y; Kan N; Okino T; Harada T; Yamasaki S; Ichinose Y; Li L; Sugie T; Imamura M
    J Surg Oncol; 1996 Jun; 62(2):78-85. PubMed ID: 8649045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin.
    Wang R; Zhang XW; Wang GQ; Chen XC; Tian L; Yang HS; Hu M; Peng F; Yang JL; He QM; Zhang W; Jiang Y; Deng HX; Wen YJ; Li J; Zhao X; Wei YQ
    Cancer Gene Ther; 2006 Oct; 13(10):940-7. PubMed ID: 16799469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
    Saji H; Song W; Furumoto K; Kato H; Engleman EG
    Clin Cancer Res; 2006 Apr; 12(8):2568-74. PubMed ID: 16638867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role.
    Schneeberger A; Koszik F; Schmidt W; Kutil R; Stingl G
    J Immunol; 1999 Jun; 162(11):6650-7. PubMed ID: 10352282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Strategies for studies on mechanism of action of antineoplastic agents].
    Kuśnierczyk H
    Postepy Hig Med Dosw; 1995; 49(1):85-96. PubMed ID: 8657622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response.
    Lee SG; Heo DS; Yoon SJ; Jee YS; Kang JO; Kim K; Kim CD; Sung MW; Kim NK
    Anticancer Res; 2000; 20(4):2681-6. PubMed ID: 10953343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.